Physician

Jay B Nayak, M.D.

According to 2025 Medicare claims, Jay Nayak, M.D. (NPI: 1427275437) practices hematology/oncology in the Greenville-Anderson-Greer, SC market, with the plurality of this provider's patient population coming from Anderson, SC. This provider's primary affiliated billing organization is ANDERSON ONCOLOGY-HEMATOLOGY CLINIC PA (NPI: 1316914161; TIN: 570749974) and primary practice location at 29621-1580. Nayak is affiliated with the Southeastern Health Partners (ACO ID: A3325), participating under the MSSP model.

Nayak's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 376 traditional Medicare patients, billed 153,561 HCPCS/CPT codes, and received $3,455,640 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,853 prescription claims across 291 beneficiaries totaling $4,253,815 in drug costs, led by Tagrisso (Osimertinib Mesylate). 2023 DME data shows 13 claims. Open Payments data shows 39 records totaling $861. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $119,534 to $3,455,640. Similarly, Part D prescription costs have risen steadily, from $474,027 to $4,253,815. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	320	1,285	$119,534
2016	329	908	$87,229
2017	241	1,168	$91,802
2018	346	1,617	$110,492
2019	392	1,955	$132,067
2020	385	1,868	$122,210
2021	395	2,007	$175,113
2022	399	23,376	$401,338
2023	371	174,445	$3,312,057
2024	376	153,561	$3,455,640

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	109	517	$474,027
2016	120	464	$655,802
2017	114	639	$330,439
2018	153	749	$848,338
2019	198	1,188	$1,446,564
2020	206	1,098	$1,692,881
2021	229	1,336	$2,249,428
2022	240	1,353	$2,941,951
2023	282	1,893	$3,717,189
2024	291	1,853	$4,253,815

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	11	$207
2016	N/R	N/R	N/R
2017	N/R	40	$10,506
2018	N/R	80	$9,747
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	13	$2,047
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	241	450	$91
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	289	644	$13
80053	Blood test, comprehensive group of blood chemicals	242	897	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	332	1,247	$8
83540	Iron level	184	409	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	33	990	$561,200
Xtandi	Enzalutamide	36	1,088	$493,419
Revlimid	Lenalidomide	25	700	$451,678
Lenalidomide	Lenalidomide	31	833	$430,102
Kisqali	Ribociclib Succinate	23	630	$342,751

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	39	$861	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jay B. Nayak, M.D.?

Tedicare shows public-source Medicare data for Jay B. Nayak, M.D. (NPI 1427275437), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jay B. Nayak, M.D. have ACO affiliation data?

Jay B. Nayak, M.D. is shown with ACO affiliation data for Southeastern Health Partners (MSSP, ACO ID A3325).

What billing organization is linked to Jay B. Nayak, M.D.?

Jay B. Nayak, M.D. is linked to ANDERSON ONCOLOGY-HEMATOLOGY CLINIC PA (billing NPI 1316914161) in the available physician profile data.

Does Jay B. Nayak, M.D. have Open Payments data?

Jay B. Nayak, M.D. has 39 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.